The sense of anticipation at this year’s annual meeting of the American Society of Clinical Oncology (ASCO) was almost palpable.
More than 38,000 delegates at the largest cancer meeting on the planet, subtitled ‘Collective Wisdom: The future of patient-centric care in research’, rushed around Chicago’s huge McCormick Center with a renewed sense of purpose.
There appeared to be an unspoken acknowledgment that the world was on the cusp of something momentous and the c-word was on the lips of many.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze